CD274 and neoplasm: Metastatic or unresectable recurrent disease is treated first-line with cetuximab and chemotherapy [19] or pembrolizumab, either as a single agent in patients with tumours expressing PD-L1, or in combination with platinum chemotherapeutics and 5-fluorouracil regardless of PD-L1 status [20].